{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T20:19:08Z","timestamp":1776284348252,"version":"3.50.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81701582"],"award-info":[{"award-number":["81701582"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.intimp.2021.107663","type":"journal-article","created":{"date-parts":[[2021,4,20]],"date-time":"2021-04-20T17:13:07Z","timestamp":1618938787000},"page":"107663","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Immunotherapeutic strategy based on anti-OX40L and low dose of IL-2 to prolong graft survival in sensitized mice by inducing the generation of CD4+ and CD8+ Tregs"],"prefix":"10.1016","volume":"97","author":[{"given":"Feng","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuxian","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pai","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinxin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunjin","family":"Zang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2021.107663_b0005","doi-asserted-by":"crossref","first-page":"625","DOI":"10.3389\/fimmu.2019.00625","article-title":"Memory T Cells in Pregnancy","volume":"10","author":"Kieffer","year":"2019","journal-title":"Front. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2021.107663_b0010","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/MOT.0b013e3283626130","article-title":"Memory T cells in transplantation - progress and challenges","volume":"18","author":"Li","year":"2013","journal-title":"Curr. Opin. Organ. Transplant."},{"key":"10.1016\/j.intimp.2021.107663_b0015","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1046\/j.1600-065X.2003.00087.x","article-title":"In remembrance of things past: memory T cells and transplant rejection","volume":"196","author":"Valujskikh","year":"2003","journal-title":"Immunol. Rev."},{"issue":"9","key":"10.1016\/j.intimp.2021.107663_b0020","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1097\/01.ASN.0000085020.78117.70","article-title":"Memory T cells: a hurdle to immunologic tolerance","volume":"14","author":"Lakkis","year":"2003","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.intimp.2021.107663_b0025","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0065-2776(10)05003-0","article-title":"OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology","volume":"105","author":"Ishii","year":"2010","journal-title":"Adv. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107663_b0030","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.trim.2015.08.005","article-title":"An immunotherapeutic strategy for prolonging graft survival in mice","volume":"33","author":"Wang","year":"2015","journal-title":"Transpl. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107663_b0035","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4049\/jimmunol.1101373","article-title":"New insights on OX40 in the control of T cell immunity and immune tolerance in vivo","volume":"188","author":"Xiao","year":"2011","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107663_b0040","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10557-013-6502-9","article-title":"Memory T cells mediate cardiac allograft vasculopathy and are inactivated by Anti-OX40L monoclonal antibody","volume":"28","author":"Wang","year":"2014","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"6","key":"10.1016\/j.intimp.2021.107663_b0045","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1182\/blood-2006-10-053801","article-title":"Costimulatory blockade of CD154-CD40 in combination with T-cell lymphodepletion results in prevention of allogeneic sensitization","volume":"111","author":"Xu","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2021.107663_b0050","doi-asserted-by":"crossref","first-page":"8575407","DOI":"10.1155\/2019\/8575407","article-title":"Efficient therapeutic function and mechanisms of human polyclonal CD8(+)CD103(+)Foxp3(+) regulatory T cells on collagen-induced arthritis in mice","volume":"2019","author":"Sun","year":"2019","journal-title":"J. Immunol. Res."},{"issue":"2","key":"10.1016\/j.intimp.2021.107663_b0055","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/imm.12603","article-title":"Different in vitro proliferation and cytokine-production inhibition of memory T-cell subsets after calcineurin and mammalian target of rapamycin inhibitors treatment","volume":"148","author":"Merino","year":"2016","journal-title":"Immunology"},{"issue":"18","key":"10.1016\/j.intimp.2021.107663_b0060","doi-asserted-by":"crossref","first-page":"e89278","DOI":"10.1172\/jci.insight.89278","article-title":"Low-dose IL-2 selectively activates subsets of CD4(+) Tregs and NK cells","volume":"1","author":"Hirakawa","year":"2016","journal-title":"JCI Insight."},{"issue":"11","key":"10.1016\/j.intimp.2021.107663_b0065","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.4049\/jimmunol.1900733","article-title":"Low-dose IL-2 therapy in transplantation, autoimmunity, and inflammatory diseases","volume":"203","author":"Tahvildari","year":"2019","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2021.107663_b0070","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/s41591-018-0070-2","article-title":"A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism","volume":"24","author":"Trotta","year":"2018","journal-title":"Nat. Med."},{"issue":"4 Suppl 92","key":"10.1016\/j.intimp.2021.107663_b0075","first-page":"S54","article-title":"Modulation of T cell responses by IL-2 and IL-2 complexes","volume":"33","author":"Boyman","year":"2015","journal-title":"Clin. Exp. Rheumatol."},{"issue":"3","key":"10.1016\/j.intimp.2021.107663_b0080","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/imm.13194","article-title":"A role for cell-autocrine interleukin-2 in regulatory T-cell homeostasis","volume":"160","author":"Chawla","year":"2020","journal-title":"Immunology"},{"issue":"6","key":"10.1016\/j.intimp.2021.107663_b0085","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/1521-4141(200106)31:6<1637::AID-IMMU1637>3.0.CO;2-T","article-title":"Control of T cell hyperactivation in IL-2-deficient mice by CD4(+)CD25(-) and CD4(+)CD25(+) T cells: evidence for two distinct regulatory mechanisms","volume":"31","author":"Wolf","year":"2001","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107663_b0090","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20191247","article-title":"Effects of interleukin-2 in immunostimulation and immunosuppression","volume":"217","author":"Pol","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.intimp.2021.107663_b0095","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.intimp.2019.03.064","article-title":"New therapeutic strategies based on IL-2 to modulate Treg cells for autoimmune diseases","volume":"72","author":"Xu","year":"2019","journal-title":"Int. Immunopharmacol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107663_b0100","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1172\/JCI46266","article-title":"IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients","volume":"124","author":"Sim","year":"2014","journal-title":"J Clin Invest."},{"issue":"12","key":"10.1016\/j.intimp.2021.107663_b0105","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1111\/ajt.12944","article-title":"Administration of low doses of IL-2 combined to rapamycin promotes allogeneic skin graft survival in mice","volume":"14","author":"Pilon","year":"2014","journal-title":"Am. J. Transplant."},{"issue":"8","key":"10.1016\/j.intimp.2021.107663_b0110","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1182\/blood-2010-10-313684","article-title":"Rapamycin and IL-2 reduce lethal acute graft-versus-host disease associated with increased expansion of donor type CD4+CD25+Foxp3+ regulatory T cells","volume":"118","author":"Shin","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.intimp.2021.107663_b0115","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/art.40773","article-title":"Suppression of murine lupus by CD4+ and CD8+ Treg cells induced by T Cell-targeted nanoparticles loaded with interleukin-2 and transforming growth factor beta","volume":"71","author":"Horwitz","year":"2019","journal-title":"Arthritis Rheumatol."},{"issue":"9","key":"10.1016\/j.intimp.2021.107663_b0120","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.4049\/jimmunol.1101291","article-title":"IL-2 simultaneously expands Foxp3+ T regulatory and T effector cells and confers resistance to severe tuberculosis (TB): implicative Treg-T effector cooperation in immunity to TB","volume":"188","author":"Chen","year":"2012","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107663_b0125","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1038\/cr.2015.3","article-title":"Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25","volume":"25","author":"Hannani","year":"2015","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.intimp.2021.107663_b0130","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4049\/jimmunol.1000800","article-title":"CD8+CD122+ regulatory T cells (Tregs) and CD4+ Tregs cooperatively prevent and cure CD4+ cell-induced colitis","volume":"186","author":"Endharti","year":"2011","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107663_b0135","doi-asserted-by":"crossref","first-page":"158","DOI":"10.4049\/jimmunol.1800976","article-title":"Regulation of diabetogenic immunity by IL-15-activated regulatory CD8 T cells in type 1 diabetes","volume":"203","author":"Stocks","year":"2019","journal-title":"J. Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2021.107663_b0140","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/TP.0000000000001011","article-title":"Donor-antigen inoculation in the testis promotes skin allograft acceptance induced by conventional costimulatory blockade via induction of CD8 + CD122+ and CD4 + CD25+ regulatory T cells","volume":"100","author":"Cong","year":"2016","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.intimp.2021.107663_b0145","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1189\/jlb.3A0613-344RR","article-title":"CD8+ CD122+ PD-1- effector cells promote the development of diabetes in NOD mice","volume":"97","author":"Arndt","year":"2015","journal-title":"J. Leukoc. Biol."},{"issue":"4","key":"10.1016\/j.intimp.2021.107663_b0150","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1038\/cmi.2014.25","article-title":"A naturally occurring CD8(+)CD122(+) T-cell subset as a memory-like Treg family","volume":"11","author":"Li","year":"2014","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.intimp.2021.107663_b0155","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jaut.2015.01.001","article-title":"Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients","volume":"58","author":"Rosenzwajg","year":"2015","journal-title":"J. Autoimmun."},{"issue":"9","key":"10.1016\/j.intimp.2021.107663_b0160","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.2337\/db13-0214","article-title":"Limitations of IL-2 and rapamycin in immunotherapy of type 1 diabetes","volume":"62","author":"Baeyens","year":"2013","journal-title":"Diabetes"},{"issue":"11","key":"10.1016\/j.intimp.2021.107663_b0165","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.2337\/db13-0669","article-title":"beta-cell-specific IL-2 therapy increases islet Foxp3+Treg and suppresses type 1 diabetes in NOD mice","volume":"62","author":"Johnson","year":"2013","journal-title":"Diabetes"},{"issue":"9","key":"10.1016\/j.intimp.2021.107663_b0170","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/j.1600-6143.2012.04133.x","article-title":"Low-dose IL-2 for In vivo expansion of CD4+ and CD8+ regulatory T cells in nonhuman primates","volume":"12","author":"Aoyama","year":"2012","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.intimp.2021.107663_b0175","doi-asserted-by":"crossref","unstructured":"Maryam, Tahvildari, Reza, Dana, Low-Dose IL-2 Therapy in transplantation, autoimmunity, and inflammatory diseases, J. Immunol. (Baltimore, Md : 1950). 203(11) (2019) 2749\u201355.","DOI":"10.4049\/jimmunol.1900733"},{"issue":"10","key":"10.1016\/j.intimp.2021.107663_b0180","doi-asserted-by":"crossref","DOI":"10.3390\/cells8101234","article-title":"IL-2 Therapy diminishes renal inflammation and the activity of kidney-infiltrating CD4+ T cells in murine lupus nephritis","volume":"8","author":"Rose","year":"2019","journal-title":"Cells."},{"issue":"5","key":"10.1016\/j.intimp.2021.107663_b0185","doi-asserted-by":"crossref","first-page":"F1274","DOI":"10.1152\/ajprenal.00616.2018","article-title":"Expansion of regulatory T cells using low-dose interleukin-2 attenuates hypertension in an experimental model of systemic lupus erythematosus","volume":"317","author":"Taylor","year":"2019","journal-title":"Am. J. Physiol. Renal. Physiol."},{"issue":"8","key":"10.1016\/j.intimp.2021.107663_b0190","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.2337\/db19-0525","article-title":"Low-Dose Interleukin-2 combined with rapamycin led to an expansion of CD4(+)CD25(+)FOXP3(+) regulatory T cells and prolonged human islet allograft survival in humanized mice","volume":"69","author":"Hu","year":"2020","journal-title":"Diabetes"},{"key":"10.1016\/j.intimp.2021.107663_b0195","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jaut.2014.10.002","article-title":"Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells","volume":"56","author":"Bell","year":"2015","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.intimp.2021.107663_b0200","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1196\/annals.1313.011","article-title":"Differential regulation of the IL-10 gene in Th1 and Th2 T cells","volume":"1050","author":"Kang","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"1","key":"10.1016\/j.intimp.2021.107663_b0205","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/10408398.2017.1358139","article-title":"Immune modulation by curcumin: The role of interleukin-10","volume":"59","author":"Mollazadeh","year":"2019","journal-title":"Crit. Rev. Food Sci. Nutr."},{"issue":"11","key":"10.1016\/j.intimp.2021.107663_b0210","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.4049\/jimmunol.1701582","article-title":"Distinct Roles for CD4(+) Foxp3(+) Regulatory T Cells and IL-10-Mediated Immunoregulatory Mechanisms during Experimental Visceral Leishmaniasis Caused by Leishmania donovani","volume":"201","author":"Bunn","year":"2018","journal-title":"J. Immunol."},{"issue":"8","key":"10.1016\/j.intimp.2021.107663_b0215","doi-asserted-by":"crossref","first-page":"3665","DOI":"10.4049\/jimmunol.1402898","article-title":"IL-10 Potentiates Differentiation of Human Induced Regulatory T Cells via STAT3 and Foxo1","volume":"195","author":"Hsu","year":"2015","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107663_b0220","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann. Rheum. Dis."},{"issue":"1","key":"10.1016\/j.intimp.2021.107663_b0225","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s12865-019-0305-0","article-title":"Low dose of IL-2 combined with rapamycin restores and maintains the long-term balance of Th17\/Treg cells in refractory SLE patients","volume":"20","author":"Zhao","year":"2019","journal-title":"BMC Immunol."},{"issue":"15","key":"10.1016\/j.intimp.2021.107663_b0230","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1182\/blood-2016-09-741629","article-title":"PD-1 modulates regulatory T-cell homeostasis during low-dose interleukin-2 therapy","volume":"129","author":"Asano","year":"2017","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.intimp.2021.107663_b0235","doi-asserted-by":"crossref","first-page":"7093","DOI":"10.4049\/jimmunol.175.11.7093","article-title":"Cutting edge: CD8+CD122+ regulatory T cells produce IL-10 to suppress IFN-gamma production and proliferation of CD8+ T cells","volume":"175","author":"Endharti","year":"2005","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.intimp.2021.107663_b0240","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/intimm\/dxn052","article-title":"CD8+CD122+ regulatory T cells recognize activated T cells via conventional MHC class I-alphabetaTCR interaction and become IL-10-producing active regulatory cells","volume":"20","author":"Rifa'i","year":"2008","journal-title":"Int. Immunol."},{"issue":"2","key":"10.1016\/j.intimp.2021.107663_b0245","doi-asserted-by":"crossref","first-page":"803","DOI":"10.4049\/jimmunol.1000661","article-title":"Cutting edge: programmed death-1 defines CD8+CD122+ T cells as regulatory versus memory T cells","volume":"185","author":"Dai","year":"2010","journal-title":"J. Immunol."},{"issue":"1","key":"10.1016\/j.intimp.2021.107663_b0250","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/JLB.1A0118-010RR","article-title":"IL-10 producing CD8(+) CD122(+) PD-1(+) regulatory T cells are expanded by dendritic cells silenced for Allograft Inflammatory Factor-1","volume":"105","author":"Elizondo","year":"2019","journal-title":"J. Leukoc. Biol."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692100299X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692100299X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T17:27:12Z","timestamp":1761586032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692100299X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":50,"alternative-id":["S156757692100299X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107663","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapeutic strategy based on anti-OX40L and low dose of IL-2 to prolong graft survival in sensitized mice by inducing the generation of CD4+ and CD8+ Tregs","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2021.107663","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107663"}}